
1. j virol methods. 2016 jul;233:51-5. doi: 10.1016/j.jviromet.2016.03.014. epub
2016 mar 26.

development validation oligonucleotide ligation assay detect
lamivudine resistance hepatitis b virus.

beck ia(1), payant r(1), ngo-giang-huong n(2), khamduang w(3), laomanit l(4),
jourdain g(2), frenkel lm(5).

author information: 
(1)seattle children's research institute, seattle, wa, usa.
(2)unité mixte internationale 174, institut de recherche pour le développement
(ird)-programs hiv prevention treatment (phpt), chiang mai, thailand;
department medical technology, faculty associated medical sciences, chiang 
mai university, chiang mai, thailand; department immunology infectious
diseases, harvard school public health, boston, ma, usa.
(3)unité mixte internationale 174, institut de recherche pour le développement
(ird)-programs hiv prevention treatment (phpt), chiang mai, thailand;
department medical technology, faculty associated medical sciences, chiang 
mai university, chiang mai, thailand.
(4)unité mixte internationale 174, institut de recherche pour le développement
(ird)-programs hiv prevention treatment (phpt), chiang mai, thailand.
(5)seattle children's research institute, seattle, wa, usa; university of
washington, seattle, wa, usa. electronic address: lfrenkel@u.washington.edu.

treatment chronic hepatitis b virus (hbv) infection with
lamivudine-monotherapy rapidly selects mutant variants high proportion of
individuals. monitoring lamivudine resistance consensus sequencing costly
and insensitive detection minority variants. oligonucleotide ligation
assay (ola) hbv lamivudine-resistance developed compared consensus
sequencing. assays detected drug resistance mutations 35/64 (54.7%)
specimens evaluated, ola detected minority mutants additional six
(9.4%). ola may offer sensitive inexpensive alternative consensus
sequencing detection hbv drug resistance resource-limited settings.

copyright © 2016. published elsevier b.v.

doi: 10.1016/j.jviromet.2016.03.014 
pmcid: pmc5074383
pmid: 27025356  [indexed medline]

